Denali Therapeutics Inc

Denali Therapeutics Inc. a biopharmaceutical company discovers and develops therapeutic candidates for neurodegenerative and lysosomal diseases in the United States and internationally. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate including BIIB122/DNL151 a small molecule inhibitor which is in phase I and phase Ib clinical trials for the treatment of Parkinson's disease; TAK-594/DNL593 which is in Phase I/II clinical trials for the treatment of frontotemporal dementia-granulin; TAK-920/DNL919 which is in Phase I clinical trials for the treatment of Alzheimer's disease. The company also develops DNL310 that is in Phase I/II clinical trials for the treatment of hunter syndrome; DNL343 which is in phase 1 clinical trial the treatment of amyotrophic lateral sclerosis (ALS); SAR443820/DNL788 which is in phase II clinical trial for the treatment of ALS multiple sclerosis (MS) and Alzheimer's disease; and SAR443122/DNL758 which is in phase II clinical trial for the treatment of cutaneous lupus erythematosus. It has collaboration agreements with Takeda Pharmaceutical Company Genentech Inc. Sanofi F-star Gamma Limited F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H F-star Biotechnology Limited Genzyme Corporation and Centogene. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco California.